A Message from LexaGene Accredited investors only can unlock this incredible investment opportunity. The early-stage company has the potential to provide significant returns, as it pioneers cutting edge technology for human and animal biopharma manufacturing. Its game-changing microbial contamination detection solution is poised to revolutionize an entire industry. • The company’s biologics in-process manufacturing microbial contamination detection market has an estimated annual TAM of ~$2.0 billion. • The company presents an opportunity to save biopharma companies millions of dollars. • The market need has been confirmed by feasibility studies and market research with leading biopharma manufacturers. In its current state, this system has a broader spectrum, and is faster and easier to use than existing microbial contamination detection products. This funding round secures the capital needed to build the 2nd Generation System needed to meet biopharma manufacturing’s specific needs. This company is solving real, costly problems for biopharma manufacturers and accredited | 
没有评论:
发表评论